Michael Tolentino’s Post

We are so happy to have these world renowned macular degeneration experts join the Aviceda family developing a drug that resolves overactivated chronic innate immune phagocytic retinal inflammation, the underlying cause of geographic atrophy, in patients with advanced dry AMD. The potential to repolarize inflammatory Microglia with AVD 104 to the neuroprotective subretinal microglial state identified by the Saban lab at Duke https://hubs.la/Q02j8cMC0 has the potential not only to halt progression of GA but rescue photoreceptors and RPE cells that have not already undergone irreversible apoptosis. The ability to rescue retinal cell and photoreceptor function was seen in a single intravitreal injection dose escalation trial of AVD 104 in patients with center involving bilateral GA patients.(SIGLEC part 1 trial) These patients had a dose dependent significant improvement in ETDRS BCVA which corroborated with multi focal ERG improvement and anatomic cessation of RPE cell loss over a follow up of 3 months . This degree of clinical efficacy resulting from AVD 104 have never been seen with any investigational drug tested or approved for GA and hold the promise of not only preventing vision loss but recovering visual function. AVD104 also represents a novel class of self associated molecular pattern mimetic designed to bind to Sialic acid Ig like lectin (SIGLEC ) family of receptors the most abundant checkpoint receptors in the immune system , which utilizes the ITIM/ITSM checkpoint pathway of PD1 (keytruda target) and which represents the main self receptor, the main pathway to prevent autoimmunity and a pathway used by cancers and infections to evade immune detection. In addition AVD 104 binds CFH as the requisite activator of the decay accelerating function of CFH. By physiologically abrogating the alternative pathway, the maintenance homeostatic role of complement can be restored versus disabled by current complement inhibitory strategies. Aviceda uses the immune systems natural immune controls to reign in age accelerated immune activation. Without these key clinical advisors, this promising novel therapy to treat the devastating condition of GA would never be realized. So please join me in welcoming theses critical advisors to the Aviceda journey.

We are pleased to share an important development from our portfolio company, Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs). Confo Therapeutics has announced the publication of groundbreaking research in Nature Communications, presenting the world’s first structure of a complex between an antibody-based agonist and a Class A GPCR. This achievement specifically focuses on the melanocortin receptor 4 (MC4R), a critical component of the melanocortin receptor family and a key regulator in the leptin-melanocortin molecular axis, which governs hunger and satiety. This significant advancement underscores Confo’s ongoing commitment to pioneering new therapeutic pathways in the treatment of diseases involving GPCRs. Click on the following link to learn more: https://lnkd.in/ehckZdp4 #BGV #ConfoTherapeutics #GPCRResearch #LifeSciencesInnovation #ObesityResearch #lifesciences #biotech Edward Van Wezel Diede Brunen

Glox Therapeutics are grateful to PACE for their support and recognising the groundbreaking potential of our unique technology. Glox Therapeutics is one of only a handful of companies to have been selected for PACE funding so far which is a true testament to the expertise of world-leading team. AMR poses a significant threat to human health globally and this grant will enable us to expand our team and accelerate the development of our innovative engineered bacteriocins to help combat two of the most life-threatening Gram Negative pathogens.

Despite the high interest in E3 ligases as a therapeutic target, they have been difficult to target in the past.   At Outrun Therapeutics, we combine our world class knowledge of E3 ligase biology and protein interactions with our proprietary discovery platform to identify first-in-class small molecule drugs targeting E3 ligases.   Our X-E3L (Crosslinking E3 Labeller) platform is able to simplify, scale, and modulate the assessment of E3 ligase targets, significantly reducing discovery time and enabling the generation of E3 ligase inhibitors that stabilise proteins.   To learn more about our elegant, engineered platform and how it is enabling us to build a robust pipeline of first-in-class, small molecule E3 ligase inhibitors to prevent protein degradation, visit our website linked in the comments below.   #e3ligase #proteinstabilisation #drugdiscovery

Neurogenic Detrusor Overactivity Treatment Market Size in the 7MM is expected to witness a major change in the study period 2020-2034: Neurogenic Detrusor Overactivity Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Neurogenic Detrusor Overactivity Therapeutics includes promising candidates that aim … Continue reading → #PharmaceuticalsBiotech

Although naked monospecifics still make up the majority of approved and in-review antibody therapeutics, ADCs and bi- and multispecifics have been carving out a greater share in recent years. Silvia Crescioli et al. explore what's driving this trend and what it means for the field of antibodies in 2025 in their recent article, which was also featured in our our journal club. You can read it here: https://lnkd.in/eBdq-Ge8 #BispecificAntibodies #Antibodies #Biotech #AntibodyTrends #FutureOfBiotech

Your weekly CRISPR Medicine News is here! 🔇 What happened in industry this week? News from Intellia Therapeutics, Inc., Allogene Therapeutics, and Fate Therapeutics Inc. 🔇New clinical trials on the way - Korro Bio, Inc. and Tune Therapeutics 🔇Research advances 🔇Reviews, and more! Get it all right here 👇 https://lnkd.in/dDaKA_ps #crisprmedicinenews #crisprmedicine #crisprnews #geneediting #cmnweekly

⏰With only 2 weeks to go, we now have limited passes remaining. Register now to sit beside the 100+ RNA targeting experts. Hear the latest insights from leading biopharma like Base4, Remix Therapeutics, Rgenta Therapeutics Inc., Biogen, Accent Therapeutics, Inc. and more. As the definitive and most comprehensive event for RNA-targeting experts, this is your opportunity to bring effective small molecule drugs to patients faster by advancing the understanding of the relationship between RNA structure and function, deciphering conformational dynamics, and designing small molecules that can effectively bind and stabilize RNA structures. Find Out More: https://ter.li/u5ozoe8 Secure Your Spot: https://ter.li/u5ozue8 #RNADrugDiscovery #RNAResearch #RNAInnovation #RNACollaboration

https://buff.ly/3VsgMLb 𝐅𝐃𝐀'𝐬 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐖𝐚𝐫𝐩 𝐒𝐩𝐞𝐞𝐝 2.0: 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 🚀🔬 💠 The FDA is taking a page from Operation Warp Speed with its new pilot program, START, designed to accelerate the development of rare disease therapies. This initiative brings together the FDA and seven leading biotech companies to streamline the approval process and bring much-needed treatments to patients faster. 💠 By fostering close collaboration between regulators and drug developers, START aims to optimize clinical trial design, refine patient selection, and enhance communication throughout the development process. 💠 Companies like Denali Therapeutics, Larimar Therapeutics, Grace Science, Neurogene, and Myrtelle are already participating in the program, working on groundbreaking therapies for a variety of rare conditions. 💠 I see this as a much-needed step in the right direction to help sponsors deal with the difficulties in drug development in this area as a result of small patient populations, lack of established endpoints, and the complexities of patient recruitment and retention. #FDA #RareDisease #Biotech #Innovation #DrugDevelopment #orphandrugs

Want to learn more about Evotec's capabilities in antibody discovery, combining in-depth understanding of disease biology and candidate derisking for developability and PK liabilities? Meet with me in sunny Montpellier